Skip to content

Probiotics in Type 1 diabetes

Role of probiotics in amelioration of immune mediated beta cell damage and improvement of glycaemic control in Type 1 diabetes mellitus

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052180
Enrollment
160
Registered
2023-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E109- Type 1 diabetes mellitus without complications

Interventions

Intervention1: Probiotics (De Simone Formulation): Arm 1: Probiotics, 1 capsule per day will be given for one year for age group 5 to 10 years. Probiotics, 2 capsule per day will be given for one year

Sponsors

Indian Council Of Medical Research (ICMR)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) Patients with type 1 diabetes mellitus, aged between 5 to 18 years. (2) diagnosed with type 1 diabetes in the last six months. (3) Informed consent for the study given by parent or a legal guardian.

Exclusion criteria

Exclusion criteria: Patients with any one of the following will be excluded. 1.Chronic medical condition that could affect gut microbiota (for example, Crohnâ??s disease, cystic fibrosis, irritable bowel syndrome, etc.). 2.Positive screening test for Celiac disease. 3.Receiving medications or supplements that could affect gut microbiota in last 15 days (for example: broad spectrum antibiotics, pro/prebiotics, laxatives, etc.). 4.Children having diarrhoea in last 2 weeks.

Design outcomes

Primary

MeasureTime frame
1) Changes in diversity and relative abundances of various species of gut bacteria (alpha & beta diversity) 2) Changes in Glycemic control parameters. â?¢ serum C -peptide levels. â?¢ HbA1c. â?¢ Insulin dose (U/kg/day). â?¢ Frequency of hypoglycaemia. â?¢ Glucose VariabilityTimepoint: 1) 0,6,and 12 months 2) 0,3,6,9 and 12 months

Secondary

MeasureTime frame
1) Changes in immune regulatory parameters 2) Changes in cytokine levelsTimepoint: 0,6,and 12 months

Countries

India

Contacts

Public ContactDr Rakesh Kumar

Postgraduate Institute of Medical Education and Research, Chandigarh

drrakesh.pgi@gmail.com7087008480

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026